Pfizer (PFE) return on equity (ROE)

Return on equity · fiscal 2025
9.0%

Pfizer (PFE) earned a return on equity of 9.0% in fiscal 2025 (the year ended December 31, 2025). That is 0.1 percentage points lower than the 9.1% of fiscal 2024. Figures as of 17 Nov 2026, 19:15 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
9.0%
Change on fiscal 2024
−0.1 pts
Highest on record
32.8%fiscal 2022
Lowest on record
2.4%fiscal 2023
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Pfizer return on equity (ROE), in more detail

Across the 19 fiscal years on record (2007–2025), the highest was 32.8% in fiscal 2022 and the lowest 2.4% in fiscal 2023. The fiscal 2025 figure is higher than in 6% of the 18 earlier fiscal years on record, whose median is 13.4%.

History · 19 fiscal years

Return on equity by fiscal year

Pfizer return on equity (ROE), year by year

Pfizer (PFE) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
20259.0% 0.1 pts down
20249.1% 6.7 pts up
20232.4% 30.4 pts down
202232.8% 4.3 pts up
202128.5% 14.0 pts up
202014.5% 10.9 pts down
201925.4% 7.8 pts up
201817.6% 12.3 pts down
201729.9% 17.8 pts up
201612.1% 1.4 pts up
201510.8% 2.1 pts down
201412.8% 16.0 pts down
201328.8% 10.9 pts up
201217.9% 5.8 pts up
201112.2% 2.8 pts up
20109.4% 0.2 pts down
20099.6% 4.5 pts down
200814.1% 1.6 pts up
200712.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Pfizer and comparable companies
CompanyReturn on equityFiscal year
Abbott Laboratories ABT12.5%2025
Novo Nordisk NVO52.8%2025
Pfizer PFE9.0%2025
Danaher DHR6.9%2025
Intuitive Surgical ISRG16.0%2025
Vertex Pharmaceuticals VRTX21.2%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PFE

Pfizer, figure by figure

Pfizer (PFE) overview: price, valuation and scorecardAll health care companies by market value

Pfizer return on equity (ROE): questions and answers

What is Pfizer's return on equity?

Pfizer (PFE) earned a return on equity of 9.0% in fiscal 2025 (the year ended December 31, 2025). That is 0.1 percentage points lower than the 9.1% of fiscal 2024.

Is Pfizer's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 6% of the 18 earlier fiscal years on record, whose median is 13.4%.

What are the highest and lowest return on equity figures on record for Pfizer?

Across the 19 fiscal years on record (2007–2025), the highest was 32.8% in fiscal 2022 and the lowest 2.4% in fiscal 2023.

How is Pfizer's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Pfizer (PFE) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/PFE/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.